Galapagos ended 2019 with cash and cash equivalents of €5.8 billion, a lucrative research and development partnership with Gilead Sciences Inc, and regulatory applications in three regions for the approval of its wholly-owned product, filgotinib for rheumatoid arthritis. The company’s founder and chief executive Onno van de Stolpe said the confluence of events had ensured the company’s independence for a period of 10 years while giving it an opportunity to significantly increase the size of its portfolio.
